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t is difficult to overestimate the need for the
definitive evaluation of cognitive function throughout
the drug development process. From a safety perspec-
tive, patients have the right either to be assured that any
new medicine will not disrupt cognitive function, or to
an accurate explanation of the likely effects they may
expect to experience. Besides safety issues, there is a
host of other reasons for wanting such information, not
least to measure the efficacy of the numerous cognition
enhancers and antidementia drugs under development.
It is the responsibility of the developers of medicines to
ensure that such data are gathered, and it is the job of
regulators to set clear guidelines on how such informa-
tion is to be obtained, and also to thoroughly scrutinize
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This paper reviews the value and utility of measuring cognitive function in the development of new medicines by reference
to the most widely used automated system in clinical research. Evidence is presented from phase 1 to 3 of the nature and qual-
ity of the information that can be obtained by applying the Cognitive Drug Research computerized assessment system to
ongoing clinical trials. Valuable evidence can be obtained even in the first trial in which a novel compound is administered
to man. One application of such testing is to ensure that novel compounds are relatively free from cognition-impairing prop-
erties, particularly in relation to competitor products. Another is to ensure that unwanted interactions with alcohol and other
medications do not occur, or, if they do, to put them in context. In many patient populations, cognitive dysfunction occurs
as a result of the disease process, and newer medicines which can treat the symptoms of the disease without further impair-
ing function can often reveal benefits as the disease-induced cognitive dysfunction is reduced. Another major application is
to identify benefits for compounds designed to enhance cognitive function. Such effects can be sought in typical phase 1 tri-
als, or a scopolamine model of the core deficits of Alzheimer’s disease can be used to screen potential antidementia drugs.
Ultimately, of course, such effects can be demonstrated using properly validated and highly sensitive automated procedures
in the target populations. The data presented demonstrate that the concept of independently assessing a variety of cognitive
functions is crucial in helping differentiate drugs, types of dementia, and different illnesses. Such information offers a unique
insight into how the alterations to various cognitive functions will manifest themselves in everyday behavior. This reveals
a major limitation of scales that yield a single score, because such limited information does not permit anything but a quan-
titative interpretation; and the concept of “more” cognitive function or “less” is manifestly inappropriate for something
as complex and diverse as the interplay between cognitive function and human behavior. Finally, the next generations of
cognitive testing are described. Testing via the telephone has just been introduced and will have dramatic effects on the logis-
tics of conducting cognitive testing in large patient trials. Testing via the Internet is not far off either, and will come fully into
play as the proportion of homes connected to the Internet increases in Europe and North America. There are no sound rea-
sons for not wishing to include cognitive function testing in the development protocol of any novel medicine.
any data presented. However, before any of this is pos-
sible, those responsible for assessing cognitive function,
ie, psychologists, need to properly define the role of cog-
nitive function in everyday behavior, develop appropri-
ate measures, and also to apply them to clinical trials.
The purpose of this paper is to describe the develop-
ment and application of the most widely used automated
cognitive function assessment system in worldwide clin-
ical research, the Cognitive Drug Research (CDR) com-
puterized assessment system.
The Cognitive Drug 
Research computerized assessment 
system (CDR system)
There is a widespread misconception that the descrip-
tion “sedative” or the warning “do not drive or oper-
ate dangerous equipment” are in some way adequate
to describe either the myriad effects that medicines
may have on everyday behavior, or the full risks and
consequences of such effects. Together with the wide-
spread use of traditional pencil and paper tests in
drug development, plus the assessment of psy-
chophysical thresholds (eg, critical flicker fusion
[CFF] frequency), this has led many to believe that
simply utilizing such assessments can properly and
fully identify the behavioral consequences of drugs.
This belief is not shared by all psychologists in this
area, particularly those who are interested in apply-
ing the principles of cognitive psychopharmacology to
clinical trials. The fundamental tenets of cognitive
psychopharmacology are:
• That there are major areas of cognitive function (eg,
attention, working memory, episodic secondary mem-
ory, the control of movement, etc) which underpin
everyday behavior.
• That these can be assessed using tests of cognitive
function.
• That these tests need to independently assess these
various functions as far as possible.
• That the tests must yield sufficient information such
that the interpretation of any change can be made
definitively.
The criticism of many traditional tests, for example, the
Digit Symbol Substitution Test (DSST), is first that they
confound a range of functions and second they are not
able to rule out speed–accuracy trade-offs. The conse-
quence of the latter problem is that volunteers are not
penalized for trading off accuracy against speed. A
change in the accuracy of performance as assessed by a
pencil and paper test such as the DSST is not a defini-
tive measure of a change in cognitive function, as it
might simply represent a change in the strategy with
which the task is performed (in the case of the DSST,
there is no way of penalizing performance if the sym-
bols are not precisely copied). Other tasks do not mea-
sure cognitive function in the first place; for example,
CFF frequency is simply a psychophysical threshold, as
is, for instance, auditory acuity, and alterations in the
threshold may occur via mechanisms that do not
involve cognitive function.
This disillusion with traditional techniques has led
many researchers to automate tests known to assess as
far as possible specific aspects of cognitive function.The
principal motivation for automation was to enable
speed of performance to be assessed at the same time
as accuracy, in order to identify speed–accuracy trade-
offs. Tests were selected on the basis of their ability to
reflect activity in particular cognitive domains such as
attention or verbal recognition.An advantage of assess-
ing speed that soon became obvious was that it was
often more sensitive than accuracy. The CDR system
has its roots in the automation of tests in the 1970s1,2
using the early laboratory minicomputers. The full util-
ity of the system was soon realized in the prototypes,
which were installed on the early microcomputers, the
most successful being the BBC. In order to facilitate the
use of the CDR system worldwide, the system was
installed on the IBM PC in the mid-1980s, where it still
remains; though it is currently being moved from the
DOS to the Windows environment. The system has a
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Selected abbreviations and acronyms
AD Alzheimer’s disease
ADAS Alzheimer’s Disease Assessment Scale
CDR Cognitive Drug Research [system]
CFF critical flicker fusion
CRT choice reaction time
DC disturbance of consciousness
DLB dementia with Lewy bodies
DSST Digit Symbol Substitution Test 
GABA gamma-aminobutyric acid
5-HT 5-hydroxytryptamine 
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range of core tests which can be supplemented by a
wide range of additional procedures. It also has the abil-
ity to facilitate the administration of traditional tests.
The core tests of the system are described in Table I.
The keyboard is not used in any test, most involving
responses made via a customized response module con-
taining YES and NO buttons. There are over 50 paral-
lel forms of the tests, which are available in most lan-
guages and are all brief (1 to 3 minutes; although some
tasks can be extended for special requirements). Dif-
ferent versions have been developed and validated for
volunteer (young and elderly) and various patient pop-
ulations.3,4 Testing can be directly linked to an elec-
troencephalograph (EEG) and evoked potential
recording in order for behavioral and electrophysio-
logical effects to be integrated.5-8 The utility, reliability,
and validity of the system have all been exhaustively
demonstrated and discussed,3,9-15 and will be further elu-
cidated together with the widespread data on the sen-
sitivity of the system in the following sections.
Screening for unwanted 
cognitive toxicity
Historically, most types of central nervous system (CNS)
drugs, and many others (eg, antihistamines), produced
impairments in human cognitive function that compro-
mise the ability of patients to undertake the activities
of daily living. Clearly, in populations where cognitive
function is already compromised, eg, elderly, demented,
or schizophrenic patients, such effects can pose very seri-
ous problems. One potential advantage of many newer
medicines under development is that they are relatively
free of such unwanted effects. Such effects (or confir-
mation of their absence) can be sought in the early
stages of drug development, and the use of the CDR
system in such research will be described for a variety of
types of compound. Another possible problem is new
medicines interacting with other medications or alco-
hol, and work in this field will also be covered.
Phase 1 single and multiple safety 
and tolerability trials
Cognitive function testing can be conducted in any
phase 1 trial, even first-time-to-man trials.16-18 The selec-
tion of tests in the latter type of trial should generally be
restricted to core tasks, the battery lasting roughly 15 to
20 minutes. There are several advantages of incorporat-
ing cognitive testing into first-time-to-man trials. One is
that the range of doses studied is almost invariably the
widest that will be administered in the development pro-
gram, and thus it is an ideal opportunity to establish the
pharmacodynamic relationship to this dose range. If no
effects are identified even at very high doses, this is a
fair prediction that none will be encountered with single
doses in the rest of the development program. Further, if
the drug shows tolerability problems or poor pharma-
cokinetics, and development is stopped, any informa-
tion about the cognitive effects (or lack of them) will
help decide whether it is worth bringing forth similar
candidates with slightly different molecular structures.
Finally, if dramatic impairments are noted in a com-
pound hoped to be free from such effects, then devel-
opment can be stopped at this point.
ME3127, a novel anxiolytic, is close to a full agonist at
some subtypes and a partial agonist at other subtypes of
gamma-aminobutyric acid–A (GABAA) receptors.
ME3127 was studied in a first-time-to-man, double-
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Table I. The tests available in the CDR system.
ATTENTION
• Simple reaction time
• Choice reaction time
• Digit vigilance
EXECUTIVE FUNCTION AND WORKING MEMORY
• Rapid visual information processing
• Semantic reasoning
• Logical reasoning
• Articulatory working memory
• Spatial working memory
EPISODIC SECONDARY MEMORY
• Word recall
• Word recognition
• Picture recognition
• Face recognition
MOTOR CONTROL
• Joystick tracking task
• Tapping task
• Postural stability task
PSYCHOPHYSICAL THRESHOLDS
• Critical flicker fusion (with and without pupil size control)
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blind, placebo-controlled, escalating single-oral-dose
study.16 Fifty-six healthy young volunteers in 7 groups
of 6 volunteers received single doses of ME3127 (1, 2, 4,
8, 16, 32, or 64 mg) and 2 further volunteers in each
group received placebo.The cognitive assessments were
completed predose, and at 2, 4, 8, and 24 hours postdose.
A dose-dependent range of impairments was detected,
the highest dose having clearly identifiable effects on a
range of measures. In a follow-up study,19 each of the 3
groups of 6 volunteers received multiple doses of
ME3127 (8, 16, or 32 mg) and 2 volunteers in each group
received placebo. Testing was performed on day 1 and
day 9. On day 1, a wide range of effects was identified, as
seen in the previous trial. Importantly, these effects
faded with repeat dosing and relatively few negative
effects were seen on day 9—in fact, on working sec-
ondary memory tasks some improvements were seen.
NS2389 acts by blocking the neuronal uptake of 
5-hydroxytryptamine (5-HT) as well as other mono-
amines such as noradrenaline and dopamine.18 The
CDR system was used to study the compound in single
doses of 1, 2, 4, 8, 16, 32, 48, and 72 mg in a double-blind,
placebo-controlled study in 64 healthy male volunteers.
Some evidence of impairment was detected at various
doses in this study.
A selective M3 muscarinic receptor antagonist (UK
76,654) developed for the treatment of irritable bowel
syndrome was studied in a parallel-group, rising-dose,
placebo-controlled, single and 9-day multiple-dosing
study.17 One of the advantages of this selectivity for the
M3 receptor is that it should be relatively free from the
unwanted cognitive impairment seen with existing non-
specific anticholinergic treatments.The CDR system was
administered six times a day in the single-dose stage and
on the first and last day of the multiple-dosing period.
No cognitive impairment was seen up to 20 mg, while at
the next dose, 40 mg, some impairments were seen. This
study gave the developers valuable information about
the dose range over which no cognitive impairment
would be seen in patients.
Phase 1 trials with internal controls
Another common procedure in phase 1 trials is to include
an internal control known to impair function, against
which the novel compound can be directly compared.
Umespirone, a novel compound with D2 antagonist and
5-HT1A agonist properties was compared with buspirone
30 mg using the CDR system in young volunteers.20 The
pattern and time course of the cognitive effects of the
two compounds were different, peak effects of bus-
pirone were seen shortly after dosing and fading there-
after, whereas the effects of umespirone persisted for
up to 23 h. Although both drugs objectively impaired
attention, buspirone reduced self-rated alertness, while
umespirone increased self-rated alertness and showed
a potential to improve secondary verbal memory.
Abecarnil, a β-carboline, and lorazepam were compared
in a single-dose trial.21 Abecarnil was found to produce a
comparable impairment to that produced by lorazepam.
In another trial in young volunteers, single doses of
amitriptyline 75 mg, hydroxyzine 25 mg, and lorazepam
1 mg were shown to have quite different profiles of cog-
nitive impairment.8 The most striking difference was the
much greater attentional impairment produced by
amitriptyline in comparison to the greater decrements to
the speed of memory processes produced by lorazepam.
Such double dissociations illustrate the value of assess-
ing different domains of cognitive function when
attempting to differentiate compounds.13 In another trial,
18 healthy male volunteers took part in a 6-way
crossover trial to contrast DU 29894 (3 and 10 mg),
a novel D2 antagonist/5-HT1A agonist, with sulpiride 
400 mg, haloperidol 3 mg, and flesinoxan, a novel selec-
tive 5-HT1A agonist.22 All the compounds produced
impairments, though the time course, magnitudes, and
cognitive profiles of effects were different. Importantly,
on some measures, each compound could be differenti-
ated not only from placebo but also from the others.
Mazapertine, a selective D2 and D3 antagonist and also
an adrenergic and 5-HT1A antagonist, was found to be
relatively free from cognition-impairing activity, though
the parallel-group design employed was less powerful
than that of the previous trial.23,24
The acute CNS effects of the β-adrenergic blocker
atenolol 100 mg and the angiotensin-converting enzyme
(ACE) inhibitor cilazapril 5 mg were contrasted in vol-
unteers using the CDR system.25 Self-ratings of alert-
ness were found to decline for both compounds yet no
cognitive effects were seen from the CDR tests for
either compound. This illustrates that volunteers can
experience reductions in alertness in the absence of
objective evidence of decreased mental efficiency. In
another trial, exactly the opposite occurred. A group of
14 elderly volunteers were dosed for 4 days with
haloperidol 3 mg, olanzapine 3 mg, or placebo in a 
C l i n i c a l  r e s e a r c h
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3-way crossover design.26 The CDR system identified
clear and widespread impairment with olanzapine 3 mg
on the first day of dosing, which was still present, though
significantly reduced on several measures, by 4 days and
had completely passed after 48 hours of washout. In con-
trast, haloperidol showed a smaller overall impairment
on the first day, which had increased dramatically by the
fourth day and was still marked on many measures after
48 hours of washout. This study predicted a clear differ-
ence between the two compounds in cognitive toxicity
with repeated dosing in patients, which has been largely
borne out by subsequent clinical trials. Interestingly,
despite being markedly impaired with haloperidol after
48 hours of washout, the volunteers reported no lower-
ing of self-rated alertness compared with predosing,
which is the opposite pattern to that described in the
previous trial. Despite this clear impairment with
haloperidol 3 mg in the elderly, another trial in this pop-
ulation, which used a 2-mg dose in an attempt to avoid
this extreme cognitive toxicity, found relatively little
overall impairment.27 On two measures, haloperidol 
2 mg was shown to be inferior to amisulpride 50 and
200 mg, the latter drug showing no impairment and
some occasional signs of enhancement. In another trial
in elderly volunteers, acute doses of moclobemide 100
and 300 mg were shown to produce little overall impair-
ment and some enhancement of memory processes com-
pared with trazodone 150 mg, which produced wide-
spread and marked impairment.28
Remacemide, a noncompetitive N-methyl-D-aspartate
(NMDA) antagonist under development for the treat-
ment of epilepsy, was found to lead to dose-dependent
cognitive impairment in acute doses up to 400 mg in a 
5-way, placebo-controlled, crossover design in 16 young
volunteers.29 Diazepam 10 mg was used as an internal
control, and produced a similar range of impairments
as remacemide 400 mg, though the profile of these
impairments in terms of the magnitudes of actions on
various aspects of function was quite distinct. However,
in subsequent repeated dosing trials, no effects of
remacemide have been discovered, despite the doses
being equivalent to therapeutically relevant equivalents
in enzyme-activated patients.30 This suggests that, for
some compounds, such as olanzapine mentioned previ-
ously, tachyphylaxis for cognitive impairment can occur
with repeated dosing.
The benzodiazepine antagonist flumazenil has been
shown to reverse the effects of midazolam on cognitive
function in healthy volunteers.31 Interestingly, despite
this effect, when given alone in three infusions of 0.5,
2.5, and 5 mg, flumazenil produced a wide range of cog-
nitive impairment in a placebo-controlled, double-blind,
crossover trial.32 Similar effects when flumazenil is
administered to patients with Alzheimer’s disease (AD)
will be reported in a later section.33
There is obvious interest in the cognitive effects of the
opioids when used to treat cancer pain.Acute oral doses
of the weak opioid dextropropoxyphene napsylate (100
and 200 mg) were contrasted to lorazepam 2 mg in a
double-blind, placebo-controlled, 4-way, crossover design
in young volunteers.34 Lorazepam 2 mg produced a wide
range of cognitive impairments in all attentional and
working and secondary memory tasks employed, as well
as self-rated alertness. Lorazepam in addition produced a
significant reduction in the frequency of fusion in the
CFF task. In contrast, the only effect seen with dextro-
propoxyphene was a reduction in the frequency at which
fusion took place in the CFF task with the 200-mg dose,
which was directly comparable to the effect of lorazepam
on this measure. This is a clear demonstration of how
misleading CFF data might be in the absence of data
from cognitive tasks. Had the only data for this study
been from the CFF procedure, it might have been falsely
concluded that dextropropoxyphene 200 mg has the
same cognition-impairing potential as lorazepam 2 mg,
whereas, as can be seen, nothing could be further from
the truth.A companion trial using the same design com-
pared acute oral doses of morphine 10 and 15 mg with
lorazepam 1 mg and placebo.35 Lorazepam again influ-
enced all tasks, though the effects were smaller in mag-
nitude than the large dose in the previous study. Inter-
estingly, self-rated scores of alertness did not show a
significant effect, illustrating the greater sensitivity of
objective tests of cognitive function. Morphine influenced
CFF in a similar fashion and to a similar degree to dex-
tropropoxyphene in the previous study. The other effect
of morphine was to disrupt episodic secondary memory,
both the ability to correctly recall words and to correctly
recognize pictures being disrupted. In the third study in
this series,36 repeated dosing of dextropropoxyphene nap-
sylate 100 mg, morphine 10 mg, lorazepam 0.5 mg, and
placebo were contrasted in a double-blind, 4-way,
crossover design in young volunteers. The volunteers
received the four doses of each treatment administered
at 4-hourly intervals over a 36-hour testing period, testing
being conducted prior to dosing, and after 4, 8, 12, 16,
Cognitive function assessment - Wesnes Dialogues in Clinical Neuroscience - Vol 2 . No. 3 . 2000
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26, 30, and 36 hours. Lorazepam affected the speed com-
ponents of all tasks employed, except that of the digit
vigilance task. Dextropropoxyphene disrupted choice
reaction time and lowered the ability to correctly recog-
nize pictures. Morphine had some effects, including a
lowering of the frequency of fusion in the CFF task.
Another study has evaluated the effects of intravenous
morphine on the performance of young volunteers.37
Here the intention was to identify a dose of morphine
that could reliably induce a cognitive deficit in a 12-
young-volunteer, crossover design in order that it might
be used as an internal standard in future evaluations of
novel opioid compounds. Three doses of morphine (2.5,
5, and 10 mg per 70 kg, infused over 15 minutes) were
contrasted to placebo in a double-blind study. Few, if any,
effects were found with the two lower doses, whereas the
10 mg/70 kg infusion slowed speed on all tasks, disrupted
picture recognition and tracking, and lowered self-rated
alertness.
The identification of residual impairment
Another unwanted effect is for hypnotics taken in the
evening to facilitate sleep to have residual effects the next
morning, ie, for the “sedative” effects to persist such that
the individual is less capable of performing the tasks of
daily living. In normal volunteers, temazepam 40 mg was
compared with flurazepam 30 mg in a double-blind,
placebo-controlled, crossover design.38 Next morning, vol-
unteers were impaired on the rapid visual information
processing task if they had taken flurazepam the night
before rather than placebo or temazepam.There were no
effects detected on two traditional measures, DSST and
CFF. Interestingly, although none of the volunteers typi-
cally experienced sleep difficulties, both hypnotics pro-
duced significant improvements in a range of aspects of
self-rated sleep quality. Flurazepam produced greater
benefits on sleep quality, at the cost of residual effects on
performance. In a follow-up trial using the same general
design, temazepam 10 and 20 mg were both found to
improve sleep quality without having residual effects on
performance.39 Finally, in a third trial, volunteers were
kept awake all night to simulate shift-work and were
administered temazepam 20 mg the morning after to
facilitate daytime sleeping.39 The trial identified that the
volunteers slept better with temazepam than with place-
bo, and again that temazepam had no residual effects on
performance.
Interaction trials
Such trials are important and are generally conducted in
volunteers, though there is no scientific reason why they
could not be conducted in patient populations. The
major reason for conducting them in volunteers is the
ease of recruitment of the subjects and the avoidance
of the complication of concomitant medications.
Alcohol interaction trials are the most common, as all
compounds carry the risk that the patient might consume
alcohol while taking the medication. Research has estab-
lished that the “everyday” perception of the effects of alco-
hol do appropriately describe the actions of alcohol. At
very low doses, there is the possibility that performance is
enhanced.40 However, above 2 units, attention is impaired,
anterograde amnesia is produced, skilled coordination is
disrupted, postural stability is decreased, and self-ratings of
alertness and clear-headedness decline.41 These are the
aspects of cognitive function which underpin the every-
day behavioral effects of alcohol.To properly conduct an
alcohol interaction trial of the effects upon cognitive func-
tion, the following conditions must be satisfied:
• The dose of alcohol must be relevant. A typical dose
range is 0.5 to 0.7 g/kg, which puts individuals around
the legal limits for driving in Europe.
• The timing of administration of alcohol and the study
compound must be arranged such that their peak con-
centrations coincide.
• Cognitive testing needs to be conducted prior to dos-
ing and at various times after.The aim here is to iden-
tify firstly whether at the time of peak absorption any
increase in the cognitive effects is identified, and sec-
ondly whether the persistence of any effects is
affected.
• The tests employed need to be sensitive to the effects
of the dose of alcohol administered and also relevant
to the known behavioral effects of alcohol (eg, to
include tests of attention, memory, coordination, and
postural stability).
• Tests not typically sensitive to alcohol should be
included to identify whether the interaction would
increase the range of cognitive functions affected by
alcohol.
Another common mistake is to allow statisticians to
design the trial as if it were a pivotal phase 3 study. It is
perfectly appropriate to have more than one outcome
measure in such trials, and the problem of multiplicity is
actually reversed. To select one primary variable, for
example, attention, and to relegate factors such as coor-
dination, memory, and postural stability to the level of
secondary outcome variables makes no sense in terms
of the everyday importance of the functions that these
tests assess. Alcohol has multiple actions on cognitive
function, and the trial must be designed to measure the
likelihood of interaction on these multiple actions. The
aim is to provide reassurance that the compound under
evaluation does not interact to produce effects that we
would not expect to see. The strength of such trials thus
lies in their demonstration that, despite measuring a
range of functions, there is little or no evidence that
interactions exist. Trials that have a single primary vari-
able face the criticism that they are not properly
addressing the full potential of the compound to inter-
act with alcohol, and thus the remit of the conclusions
based on the trials should be restricted to the func-
tion(s) assessed as the primary variable(s).
There are two basic design types in most interaction tri-
als.The most simple is the classic 2×2 factorial crossover
design generally involving acute administration of the
study compound. In such a design the four combination
possibilities are covered:
• Placebo alcohol and placebo study compound.
• Placebo alcohol and active study compound.
• Active alcohol and placebo study compound.
• Active alcohol and active study compound.
The major alternative design involves multiple dosing
with the study compound. Here, two multiple-dosing
periods take place, one with the active study compound
and the other with the placebo study compound. After
a sufficient time for the study compound to reach
steady state, 2 test days, separated by 2 or 3 days, occur
on which active alcohol and placebo alcohol are admin-
istered, in counterbalanced order between volunteers.
The two dosing periods are either crossed-over with
an adequate washout interval or a split-plot design is
used. The latter is generally the case if the dosing
period is 14 days or more. The efficiency of the
crossover design here stands comparison with the 2×2
factorial, which is impressive considering the require-
ment of repeated dosing.
The smallest sample size in such trials is 12,42 and in
some studies as many as 30 volunteers are tested.43 The
following trials all used the classic 2×2 factorial design,
and found clear effects of alcohol but no potential of
the study compounds to produce interactions. Four
used young volunteers, no interaction being found for
the antiepileptic tiagabine,42 the NMDA antagonist
remacemide,43 the antiobesity compound sibutramine,44
lorazepam, or the β-carboline abecarnil.21 In a trial with
elderly volunteers, no interactions were detected for the
muscarinic agonist SB-202026.45 The multiple-dosing
design was employed in a crossover study to evaluate
the interaction potential of alcohol and the selective
serotonin reuptake inhibitor (SSRI) fluvoxamine in
young volunteers.46 No signs of an interaction were iden-
tified in this trial. In an unusual design, the effects of two
doses of moclobemide (100 and 300 mg), trazodone 150
mg, and placebo were evaluated in elderly volunteers.28,47
Twelve of the volunteers had the four dose conditions in
a crossover design, on each occasion receiving a place-
bo alcohol dose.Twelve further volunteers had the same
four study compound conditions, but also received alco-
hol 0.5 g/kg on each occasion. No interactions with alco-
hol were identified for either compound.
Drug–drug interaction trials follow the same basic
design as alcohol interaction trials and the same basic
design rules generally apply, with the added complica-
tion that in some trials it is desirable for both drugs 
to reach steady state. In a series of trials looking for
interactions with the SSRI sertraline, parallel-group
designs were employed. In one trial, phenytoin was
administered to all volunteers for 24 days.48 From day
8 onwards, sertraline was administered to half the vol-
unteers and placebo sertraline to the other half. Cog-
nitive testing was performed prior to dosing and
repeatedly postdosing on days 0, 7, and 24. There was
no evidence that phenytoin alone impaired perfor-
mance or that when dosed with sertraline any cogni-
tive effects appeared. In a second trial, carbamazepine
was administered to all volunteers for 32 days.49 From
day 16 onwards, sertraline was administered to half of
the volunteers and placebo sertraline to the other half.
Cognitive testing with the CDR system was performed
repeatedly on days 1, 15, and 32. Carbamazepine
impaired attentional efficiency, slowing performance
on simple reaction time, choice reaction time, and digit
vigilance. These effects were still evident after 32 days
of dosing. There was no evidence that sertraline had an
influence on this disruption to attention, nor did any
other effects emerge when sertraline was codosed with
carbamazepine. In a third study,50 placebo was given
on day 1, and a single dose of haloperidol 2 mg was
administered to 24 healthy young volunteers on day 2
and again on day 25 of the study period. Sertraline
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was administered from day 9 onwards to 12 volun-
teers, the other 12 receiving placebo sertraline. The
CDR system was administered repeatedly on days 1, 2,
and 25. Haloperidol produced impairments in atten-
tion on day 2 of the study, yet amazingly, with no inter-
vening dosing, the second single dose administered 23
days later produced greater impairment. On measures
affected the first time, the effects started sooner and
were of greater magnitude, while functions not
affected on day 2 were impaired on day 25. Of 20 mea-
sures, 10 were impaired to a significantly greater
extent on day 25 than day 2. This effect reflected a
phenomenon seen in animals dosed with haloperidol
termed “time-dependent sensitization” and was the
first demonstration that such a phenomenon exists in
man. In other drug–drug interaction work, no evidence
was obtained for an interaction between the SSRI flu-
oxetine and the 5-HT1A agonist flesinoxan.51
In the 11 studies described above, no interactions were
seen.The same was true of the first of two interaction tri-
als conducted with the novel antihypertensive moxoni-
dine.52 In the first trial, no interaction between moxoni-
dine and the antidepressant moclobemide 300 mg was
identified. However, in the second study, a clear interac-
tion between moxonidine and lorazepam 1 mg was iden-
tified. In this trial, lorazepam 1 mg produced the profile
of impairment characteristic of this type of benzodi-
azepine. Moxonidine 0.4 mg dosed alone produced no
effects, but when the two drugs were codosed, the impair-
ment identified was significantly greater than that of
lorazepam 1 mg. This interaction was seen for the fol-
lowing CDR measures: speed of detections in the digit
vigilance task, simple reaction time, choice reaction time,
and visual tracking.These were clear interactions, which
would disrupt the attentional capacity of patients taking
lorazepam 1 mg and moxonidine 0.4 mg together. His-
torical data, however,34 showed that the impairments with
the combination were no greater than what would be
produced by lorazepam 2 mg, which will give clinicians a
frame of reference when advising patients of the likely
consequence of taking the two medications together.
Screening for desired 
cognitive effects
Here the purpose of cognitive testing is to identify
desired cognitive effects, which are for the most part
either reversals of existing deficits or improvements to
normal functioning. Over the last 20 years, there has
been a massive investment in research into agents to
treat dementia, particularly AD. This has in turn led to
interest in treating a range of conditions in which cogni-
tive function is impaired, not least normal aging. The
implicit assumption of many researchers in this field is
that impairments in function are potentially capable of
being reversed, but that normal function cannot be
improved.53 This assumption is fallacious, as will be illus-
trated in the next section.
Cognition enhancement
A program of research was initiated at Reading Uni-
versity in the early 1970s into the effects of nicotine on
human attention. The basis for the research was the
known effects of nicotine on the neurotransmitter
acetylcholine, and the aim of the research was to pro-
vide evidence at the human level that nicotine, by
enhancing cholinergic function, would improve human
attention.1,2 The research showed that nicotine adminis-
tered via smoking was capable of improving perfor-
mance on visual and auditory vigilance tasks,1 the rapid
visual information processing task,54,55 and the digit vig-
ilance task.56 Further research showed that improve-
ments on the rapid visual information processing task
could be seen puff by puff,57 that higher-nicotine-yield
cigarettes improve performance more than lower
ones,54,58 that the ability to detect the targets was
improved together with the speed with which the tar-
gets were detected, and that the latency of the evoked
potential to the targets was shortened by the same
amount as the latency of the response was reduced.5 A
review of 12 years of this research illustrated the robust-
ness of these findings: “Every nicotine-containing ciga-
rette we have studied improves performance. Improve-
ments occur irrespective of the duration of testing, the
speed of presentation of the digits, the density of targets,
whether or not subjects smoke while performing,
whether or not they are filmed, whether or not electro-
cortical activity is measured in another laboratory, and
whether testing is carried out in the morning or after-
noon.”59 This work has provided valuable information
on the pharmacological basis of the smoking habit.60 As
the research was conducted in healthy young volun-
teers, it demonstrated that enhancements to cognitive
function can be detected in this population. As con-
vincing as the findings were, it was still necessary to
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prove beyond reasonable doubt that they were due to
nicotine. Thus, nicotine was administered in tablet form
in various studies. These tablets were found to improve
performance on the vigilance task61 and on the rapid
visual information processing task.62 Importantly, the
improvements in vigilance occurred in smokers and
nonsmokers, and on the rapid visual information pro-
cessing task nicotine tablets improved the speed and
accuracy of nonsmokers. This work has been widely
replicated in other laboratories (for reviews, see refer-
ences 58 and 63). Of particular interest are improve-
ments in rapid information processing seen with nico-
tine gum64-66 and with a nicotine inhaler.67 This body of
work identified that improvements in normal cognitive
function could be produced by pharmacological agents,
and showed that computerized tasks were particularly
suitable for identifying such improvements, notably
those in accuracy and speed. It also helped establish
the role of the cholinergic system in human attention.
Caffeine has long been believed to enhance mental
alertness, and a large body of literature has found data
consistent with this; though the effects identified by the
CDR system have not been marked or widespread.68-70
Similarly, some limited effects have been seen with glu-
cose drinks, but again these effects are not robust.71,72
A more recent series of trials have identified oxygen
as a cognition enhancer. Here, short (30 seconds to 3
minutes) administrations of pure oxygen have been
shown to enhance performance on a wide range of tasks
from the CDR system in healthy young73-80 and
elderly81,82 volunteers.This wide-ranging work has shown
that attention and working and episodic working mem-
ory can be enhanced by oxygen in normal volunteers,
and again supports the concept that enhancements can
be made to nonimpaired cognitive function.
Considering the work described above, it is not surpris-
ing that potential cognition enhancers are screened in
phase 1 trials with young volunteers. NS2330, a com-
pound that combines the inhibition of neuronal
monoamine (noradrenaline, dopamine, and serotonin)
reuptake with stimulation of the cholinergic system in
the prefrontal cortex and hippocampus, was studied in a
first-time-to-man safety and tolerability trial.83 At 1- and
2-mg doses, the compound produced a wide range of
enhancements on CDR assessments, including improve-
ments in attention, working memory, and episodic mem-
ory, as well as increasing self-rated alertness. These
effects were obtained despite the fact that only 6 vol-
unteers received each active dose and 4 received
placebo. The effects seemed particularly long-lasting,
and, in a follow-up trial,84 higher doses were studied and
effects were assessed up to 360 hours following a single
dose. Benefits were seen which were of the same profile
as those seen in the previous study and, remarkably,
some benefits were seen at 360 hours. In another first-
time-to-man trial, a range of doses of NS2359, a nora-
drenaline, dopamine, and serotonin reuptake inhibitor,
was studied in 56 volunteers.85 The compound showed
clear cognition-enhancing properties, particularly with
regard to attention and episodic memory. These trials
indicate that important evidence on the potential of
compounds to enhance cognitive function can be
obtained simply by including cognitive testing in safety
and tolerability trials, which need to be conducted as
part of the drug development process. Further evidence
of the utility of this approach comes from a multiple-
dosing safety and pharmacokinetic trial in which CDR
testing was introduced to evaluate the potential CNS
actions of GTS-21, a selective agonist at the α7 nico-
tine receptor.86 Here, despite having only 12 volunteers
on active medication and 4 on placebo, a clear profile of
enhancements was seen for attention and working and
secondary memory. This profile was unexpected, as the
effects of nicotine are primarily limited to attention and
information processing and no consistent effects have
been seen in the world literature of beneficial effects of
nicotine on memory.58,63 This indicates that the selectiv-
ity of the compound to the α7 subtype of the receptor is
a particularly promising avenue for cognition enhance-
ment. Finally, in a crossover study with 12 young volun-
teers, the anticholinesterase physostigmine was found to
produce a range of enhancements of attention and
episodic memory.87 This is one of the few published
demonstrations of an anticholinesterase improving
function in unimpaired volunteers.
Many researchers feel that the elderly are better tar-
gets for cognition enhancers due to age-based cognitive
decline. Certainly the CDR system is highly sensitive to
such declines (see, for example, reference 88), though
generally there is little systematic evidence that the
elderly respond more readily to cognition enhancers
than the young.81,82 S-12024, a pronoradrenergic com-
pound was found to improve cognitive function in a
multiple dose safety and tolerability trial.89 Interest-
ingly, here the improvements occurred in aspects of
function which had declined when the population was
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compared with younger volunteers. HOE 427, an
ACTH4-9 analogue (ACTH: adrenocorticotrophic hor-
mone), was found to produce some evidence of
improvement in a 4-way, crossover design in 20 elderly
volunteers.90
Serendipity can also play a part in drug development.
The CDR system was included in trials of flesinoxan, a
5-HT1A agonist, in order to ensure the compound was
relatively free from cognition-impairing potential.
Unexpectedly, cognition enhancement was seen, and,
in a follow-up study, these effects were confirmed in
young and elderly volunteers, though the effects were
greatest for the eldest volunteers, providing evidence
relevant to the debate referred to in the previous para-
graph.91 Further, in four of the interaction trials, bene-
ficial effects of the study compounds were seen. This
occurred for moclobemide in both elderly47,92 and
young volunteers,52 and also for sibutramine44 and SB-
202026.45
Scopolamine model of dementia
Another part of the research program initiated at Read-
ing University that was mentioned at the beginning of
the previous section was to identify the cognitive effects
of the muscarinic cholinergic antagonist scopolamine.
Here, the cholinergic system was further implicated in
the control of human attention by trials that showed
that cholinergic blockade disrupted attention on the
vigilance task93 and also on the rapid visual informa-
tion processing task.62 Subsequent research extended
the range and scope of such findings, showing that all
measures of the CDR system were sensitive to the
effects of cholinergic blockade.94-99 Further work has
identified the relationship between the behavioral
deficits induced by cholinergic blockade and the phar-
macokinetics of scopolamine,100 EEG changes,94 positron
emission tomography (PET) changes,101 future cogni-
tive decline in the elderly,102,103 and the cognitive deficits
seen in AD.104-107
The growing recognition that cholinergic deterioration
underpinned the cognitive deficits in AD, plus the
response of AD patients to anticholinesterases and the
known cognitive effects of cholinergic blockade with
scopolamine in volunteers, led to the idea that scopo-
lamine could produce a model of some of the core cog-
nitive deficits in AD. This idea was further developed
when nicotine was found to reverse the effects of scopo-
lamine on attention in young volunteers.108 The oppor-
tunity has thus existed for over 16 years to utilize a
model to help screen potential anti-Alzheimer drugs in
phase 1. The validity of this model has been widely
established109-112 and a wide variety of drugs have been
screened.
The model is particularly sensitive to anticholinesteras-
es, for example, physostigmine 2 mg subcutaneously
has been found to rapidly and completely reverse the
impairment produced by scopolamine on all CDR
tasks employed, yet these effects were only temporary
and had faded an hour later.113 This mimics the clinical
situation perfectly, many early trials showing brief
improvements in AD patients during infusions of
physostigmine, which faded rapidly on cessation of the
infusion. A further trial has confirmed this rapid but
temporary action of physostigmine and has further
shown it to be strongly dose-dependent.114 In a further
series of studies, velnacrine, an analogue of the anti-
cholinesterase tacrine, was found to produce wide-
spread reversal of the cognitive impairment on CDR
tasks produced by scopolamine.113,115,116 The drug was
then administered to AD patients and improvements
were seen on some of the CDR tasks that reversals had
been identified in the scopolamine model.115,116 The
model is sensitive to a range of compounds, even those
without known cholinergic effects. The classic nootrop-
ics aniracetam and piracetam have shown activity in
the model,117 as has tenilsetam,118 though 3OH-ani-
racetam (Ro 15-5986) showed no activity.47,119 The
monoamine oxidase inhibitor moclobemide has been
shown to reverse the effects of scopolamine,47,119 as has
the partial agonist at the strychnine-insensitive glycine
site on the NMDA receptor, D-cycloserine, in both
young and elderly volunteers.120,121 The effects of the lat-
ter compound were particularly interesting as they
were limited to the working and episodic memory
effects of scopolamine. FK960 has shown a widespread
ability to reverse the effects of scopolamine.122 Quite a
number of compounds have not shown sensitivity in
the model, despite performing very well in various ani-
mal models, but these have not been released into the
public domain. One compound that failed to have any
effect on the impairment due to scopolamine was can-
doxatril, a prodrug of the atriopeptidase inhibitor, can-
doxatrilat, which increases circulating levels of the
peptide hormone atrial natriuretic peptide and inhibits
the degradation of endogenous enkephalins.123
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Alzheimer’s disease
Computerized testing with demented patients is per-
fectly feasible provided the tests are appropriately
designed, short in duration, and easy to explain and fol-
low, the material is clearly visible, the responses are sim-
ple to make, and the negative feedback kept to a mini-
mum. The mid-1980s saw the development of the first
CDR prototypes,4 and the CDR system currently used
for demented patients has now been widely validated.3,124
The methodology has now been widely disseminated,125
and the system has been used to identify the full impair-
ments in attention which accompany the widely recog-
nized memory deficits in AD.105-107,126 These attentional
impairments have been shown to be a result of cholin-
ergic dysfunction104,106,107 and thus to be legitimate targets
for anti-Alzheimer drugs.104,127 The system has been
shown to be particularly sensitive for differentiating dif-
ferent types of dementia from AD, for example, Hunt-
ington’s disease.128 It has been contrasted favorably with
a wide range of traditional measures in dementia includ-
ing the Mini-Mental State Examination,3,128 the
Alzheimer’s Disease Assessment Scale (ADAS),128 the
Mattis Dementia Rating Scale,128 the Wechsler Memory
Scale,128 the Cambridge Cognitive Examination (CAM-
COG),129 the Kendrick Battery,3 the Kew Test of mem-
ory, aphasia, and parietal function,3 and the Stockton
Rating Scale.3 In trials where the sensitivity and dis-
criminability of the CDR system in AD and other types
of dementia have been directly compared with various
traditional assessments and the ADAS, the CDR sys-
tem has been found to show higher discriminability than
the other techniques, and also to be more sensitive in
identifying AD patients than traditional measures as
well as the ADAS.128 Such work has led the International
Working Group on Dementia Drug Guidelines to rec-
ommend that future AD trials incorporate assessments
of attention (currently not assessed by the cognitive sub-
scale of the ADAS), and that computerized systems
should be used alongside traditional techniques wher-
ever possible.130
The CDR system has been used in various therapeutic
trials. The CDR system was the primary outcome vari-
able in a large Food and Drug Administration
(FDA)–approved multicenter trial of D-cycloserine in
AD.131,132 Sadly, the compound showed no signs of effica-
cy, despite showing promise in single doses in animal
work and the scopolamine model.120,121 However, in sub-
sequent publications, the beneficial effects seen in single
doses in animal work disappeared with repeated testing,
suggesting that this tachyphylaxis might have also
occurred in the AD study.131 S-12024 was tested in 
a 4-week acceptability and clinical activity trial of S-
12024 in 53 inpatients with moderate-to-severe AD,
but no clear signs of positive effects were identified.133
Various anticholinesterases have been shown to be
effective in improving both attentional and memory
function, including tacrine,134 velnacrine,115,135 and galan-
thamine.134,136 Importantly, the effects on attentional
function are large; the improvements with galanthamine
can, for example, take patients 40% back toward scor-
ing normally for their age.136
The work with velnacrine indicates that improvements
can occur rapidly with anticholinesterases,115,135 and early
phase 2 trials would benefit greatly if a range of doses
could be rapidly evaluated. In fact, it is quite feasible
that many compounds could produce acute improve-
ments, as have been seen with volunteers in the previous
section. To evaluate such effects, short repeatable tests
would be necessary, and one recent study suggests this is
feasible in AD patients using the CDR system.33 Here,
the acute cognitive effects of intravenous flumazenil
were identified in AD patients by assessing them prior
to infusion and again at 15, 40, and 240 minutes later.
Three tests from the CDR system were employed, two
to measure attention (simple and choice reaction time),
and a test of episodic secondary memory (picture recog-
nition).This enabled a double-blind, placebo-controlled,
single-dose, 2-way crossover trial to be conducted in AD
patients, the first time to the knowledge of these authors
that multiple repeated testing over so short a period has
been possible in AD. The sensitivity of the system was
demonstrated by identifying short-term impairments
with the compound in two of the tasks, despite the trial
only having 11 patients.
Dementia with Lewy bodies
An important newly identified dementia is dementia
with Lewy bodies (DLB), believed to account for up to
20% of all dementias, and previously largely mistaken
for AD.137-141 The condition is known to be more cholin-
ergically specific than AD, and thus more likely to
respond to cholinergic treatment. There is also a larg-
er nicotinic component to the cholinergic damage.
Here, unlike other dementias, attentional deficits are
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recognized as a core symptom of the disease, and
recent work with the CDR system has shown greater
attentional impairments in DLB patients than in AD
patients, while showing a double dissociation with
DLB patients having smaller verbal memory deficits
than AD patients.137-141 The condition can also be dif-
ferentiated from vascular dementia.142 In comparative
work using the CDR system with four types of demen-
tia, AD, DLB, vascular dementia, and Huntington’s dis-
ease, it is clear that each has its unique profile of cog-
nitive impairment over the various tasks and measures.
Any scales therefore that yield single scores for cogni-
tive impairment will not properly reflect the diversity
of the cognitive impairment seen nor the implications
of this diversity for the true behavioral profile of the
different diseases. The cholinergic nature of the atten-
tional deficits has been further confirmed by compar-
ing nonhallucinators with patients who do halluci-
nate.143 It has been shown that hallucinators have
greater cholinergic deficits than nonhallucinators, and
comparing the two groups on CDR tests of attention
showed greater attentional deficits in the hallucinators.
Disturbances of consciousness (DCs) are a key clinical
diagnostic feature in DLB, while they preclude a clini-
cal diagnosis of probable AD. Despite the prevalence
and importance of this key symptom, current identifi-
cation of DCs relies solely on expert clinical judge-
ment, resulting in poor interrater reliability and inac-
curate identification. In one study, 129 patients (37
DLB, 60 AD, and 33 healthy elderly volunteers) with
assigned clinical DC scores, were assessed using the
CDR 90-second choice reaction time task.144 Correla-
tions between variability (standard deviation) within
the 90-second choice reaction time trial and clinical
measures of DC where investigated. Variability in
attentional performance across the 90 seconds strong-
ly correlated with clinical DC scores, remaining signif-
icant when mean reaction time was accounted for
using the coefficient of variation. An optimal cutoff
score in choice reaction time variability, derived from
the first 35 subjects, discriminated AD from DLB
patients with a specificity of 95%. Variability in a 90-
second attentional trial appears to be a sensitive, accu-
rate marker for DCs, with substantial implications for
the identification and description of this key symptom.
These findings have considerable implications for the
existing operationalized clinical diagnostic criteria for
AD and DLB.
Finally, in the first international therapeutic clinical trial
in DLB (ENA-INT-03), in which the CDR system was
used as an outcome measure to test the efficacy of the
anticholinesterase rivastigmine, a marked and highly sig-
nificant response to treatment was identified on the
CDR tasks, particularly the attentional tasks, which
faded when treatment was withdrawn.145 These effects
were large in magnitude and more substantial than those
typically identified in AD using the ADAS. This identi-
fies DLB as an important target for future work with
drugs acting via cholinergic and particularly nicotinic
mechanisms.
Cognitive deficits in various populations
Using the CDR system, various profiles of cognitive
impairment have been seen in a range of clinical and
psychiatric populations. A range of deficits in cognitive
function has been seen in young first-time-diagnosed
schizophrenic patients compared with aged, matched
controls.146 Severe cognitive deficits have been identified
in patients suffering from chronic fatigue syndrome147 as
well as patients with multiple sclerosis.148,149 Milder deficits
have been seen in hyperthyroid patients.150 Diseases asso-
ciated with the carotid artery can also lead to cognitive
impairment, including carotid sinus syndrome151 and
carotid sinus hypersensitivity.152 Further, cognitive impair-
ment can be identified following carotid endarterec-
tomy.153,154 Cardiovascular disease can also lead to cogni-
tive impairment. Recent work has shown widespread
deficits in elderly hypertensive patients compared with
normotensives,155 and a range of impairments have been
seen in patients with various cardiovascular conditions.156
Cardiac bypass surgery has long been associated with
subsequent cognitive impairment, and a recent trial has
confirmed these deficits and shown that patients receiv-
ing minimal invasive cardiac procedures have little or
no residual impairments.157 Stroke produces cognitive
impairment equivalent to mild-to-moderate AD,158 which,
although the symptoms recede over the first 8 weeks,
fairly severe deficits still remain at this time. This study
also showed that the various CDR measures correlated
well with the traditional instruments in this field, the
Barthel, the Rankin, and the NIH indexes.158 Traumatic
head injury is clearly associated with severe cognitive
deficits,159 while even minor head injury can be associ-
ated with persistent cognitive impairment.160 Diabetes is
associated with fairly marked cognitive impairment.161 It
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is important to note that, as has been seen earlier in this
section with different types of compound and different
types of dementias, each of these conditions has a dif-
ferent profile of impairments, and while many may show
impairments for the same tasks, the relative impairments
for the various measures is always different, giving each
condition a characteristic profile.
A number of other conditions can induce cognitive
impairment. In one trial, junior housemen having
worked a weekend on a busy surgical oncology ward
were found to show measurable cognitive impairment
on reporting to work the following Monday morning
compared with Mondays following weekends when they
were off-duty.162 Chemicals found in the workplace have
been shown to disrupt functioning. Dentists exposed
chronically to mercury were found to have mild cogni-
tive deficits,163 while workers exposed to solvents on a
long-term basis showed severe deficits.164 Users of ecsta-
sy (3,4-methylenedioxymethamphetamine [MDMA])
have been found to have fairly selective deficits to
episodic memory.165 Carbon monoxide poisoning has
been shown to result in severe deficits.160 Finally, mag-
netic fields of the type associated with some domestic
appliances have been shown to disrupt functioning166;
and an improvement in choice reaction time was seen
with a simulated mobile phone signal, suggesting that
mobile phones may alter cognitive function.167
In the field of oncology, cognitive testing with the CDR
system has proven practical and acceptable. Hospital-
ized patients taking opioids for cancer pain have been
successfully tested,168 as have patients receiving either
chemotherapy of rIL-2 for colorectal cancer.169,170 rIL-2
was shown to produce marked declines, which reversed
following the cessation of immunochemotherapy.Testing
was possible daily during three successive 8-day cycles
with 14-day intervals. Performance under chemother-
apy was extremely stable over the trial, with the large
impairments due to rIL-2 returning to preinfusion levels
a week later.
Midazolam is commonly used as a preoperative anxi-
olytic, particularly in dental work. In a recent trial in
which the CDR was administered to dental patients,
impairments have been shown to be more widespread
following midazolam administration than following
nitrous oxide.171 The important contribution of this work
to practice in dental hospitals was recognized in an edi-
torial in the same issue of the British Dental Journal,
which endorsed the recommendation that patients
should receive written instructions on leaving the units
due to the persistent amnesia measured by the CDR
tests following midazolam. Temazepam is also used as a
premedication in day case surgery. In one trial, patients
were assessed prior to and several times postsurgery;
temazepam or matching placebos being administered
preoperatively.172 The effects of anesthesia were easily
detected by the cognitive tasks, as were the additional
but temporary impairments produced by temazepam.
Reversing deficits in various patient populations
In chronic fatigue syndrome, the deficits in attention were
shown to be temporarily reversed by the administration
of oxygen.173 In elderly depressed patients, those treated
with placebo showed an increase in cognitive impairment
on various tasks over a 50-day period.174 Those who were
treated with nortriptyline showed improvements in
Hamilton Depression Rating Scale (HAM-D) scores and
also showed a smaller decline in performance over the
50-day period. The group of patients treated with
moclobemide, however, showed no decline but actually a
significant enhancement in performance over the study.
This study suggests that the cognitive impairment associ-
ated with depression will worsen if it is not treated. Even
a tricyclic compound like nortriptyline, which will impair
function under normal conditions, will show some degree
of improvement as the symptoms of depression are
treated and the cognitive impairment remits. However,
compounds such as moclobemide, which are free from
unwanted effects, and possible cognitive enhancers will
improve function in such patients by treating depression
and having no liability to compromise efficiency.
In elderly hypertensive patients who were on long-term
treatment using the β-blocker atenolol, a trial was per-
formed by switching half of the patients to the ACE
inhibitor cilazapril.175 Cognitive function was assessed
using the CDR system over a 20-week period. Signifi-
cant improvement in choice reaction time and a pattern
of enhancement in many other assessments was seen in
the patients switched to cilazapril.This trial suggests that
β-blocker withdrawal should be considered for any
elderly patient showing signs of cognitive dysfunction.
The effects of herbal medicines are becoming increas-
ingly studied as the push towards evidence-based medi-
cine spreads into this field. Ginkgo has been shown to
improve function in elderly people with mild cognitive
impairment in a 3-month, placebo-controlled, double-
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blind trial.176 Such effects have also been seen in patients
with more severe cognitive decline.177 Finally, a combi-
nation of Ginkgo biloba and Panax ginseng has been
shown to have a dose-dependent benefit in volunteers
fulfilling the criteria for neurasthenia, a condition asso-
ciated with fatigue.178 The benefits are primarily to mem-
ory performance, and the relative contribution of ginkgo
and ginseng to these effects is currently under study.
Conclusions 
and future directions
Computerized testing of cognitive function has now
come of age and is available for any trial in any popula-
tion. It can be conducted throughout the development
process, from the first time the compound is given to
man right through the phase 4 trials. The information
that such testing can yield is vital to “go–no go” deci-
sions, and the earlier in the development program the
testing is introduced, the earlier such information is
available and the more appropriate are the decisions
made concerning future development. While trials can
be designed with the specific intention of assessing cog-
nitive function, cognitive testing can also be integrated
into almost any study design without compromising the
initial aims of the study.
It is also clear that the concept of independently assess-
ing a variety of cognitive functions has paid dividends
in helping differentiate drugs, types of dementia, and
different illnesses. Such differentiations are crucial as
they permit a unique insight into how the alterations to
various cognitive functions will manifest themselves in
everyday behavior. This reveals the clear limitation of
scales that yield a single score; while such information
is rapidly digestible, it does not permit anything but a
quantitative interpretation; and the concept of “more”
cognitive function or “less” is manifestly inappropri-
ate for something as complex and diverse as the inter-
play between cognitive function and human behavior.
The next stages for cognitive testing are to achieve inde-
pendence from the current platform for testing, the
stand-alone PC. There are two major opportunities for
doing this. The first is to conduct cognitive testing over
the telephone, and such a version of the CDR system
has been developed and validated,179,180 and is now in use
in clinical trials. Here, a central computer using interac-
tive voice-response techniques presents the test stimuli
over the telephone, and the patient responds by pressing
the touch keys. Reaction time and accuracy are assessed,
and these have shown high correlation with the same
tests administered with computers.This system can auto-
matically and simultaneously test over 100 patients in
virtually any location. The patients can be assessed at
home, at frequent intervals, without the involvement of
study personnel or the completion of any paperwork.
Further, the data are verified and processed during test-
ing and automatically stored in a central database. This
highly efficient system can be used in trials of any size
and duration. Clinical research now has a methodology
for the remote assessment of cognitive function.
The second opportunity is testing via the Internet. Proto-
types are currently running and a full system is expected
to be online by early 2001. Again the benefits are the
numbers of patients who can be assessed at any time as
well as the ease of gathering and verifying the data. This
system will be of greater initial utility in North America
where a greater number of homes are connected to the
Internet. However, it is likely that Europe will catch up in
a few years and a second methodology for the remote
assessment of cognitive function will be available.❑
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El valor de la evaluación de la función cognitiva en el desarrollo de fármacos
Este artículo revisa el valor y la utilidad de la medición de la función cognitiva en el desarrollo de nuevos
fármacos en comparación con el sistema automatizado más ampliamente utilizado en la investigación clíni-
ca. Se presenta la evidencia desde la fase I hasta la fase III de la naturaleza y calidad de la información, la
que puede ser obtenida al aplicar el sistema de evaluación computarizado de la investigación cognitiva de
fármacos a los actuales ensayos clínicos. Se puede obtener una evidencia de gran valor aun en el primer ensa-
yo en que se administra un nuevo compuesto al hombre: una aplicación de esta prueba sirve para asegurar
que los nuevos compuestos están libres de propiedades que deterioren la función cognitiva, particularmen-
te en relación con productos de la competencia. Por otra parte se asegura que no ocurran reacciones inde-
seables con alcohol u otros medicamentos, o si ocurren, se está en conocimiento de ellas. En muchos grupos
de pacientes, la disfunción cognitiva se produce como resultado del proceso patológico, y los fármacos más
recientes que pueden tratar los síntomas de la enfermedad sin un adicional deterioro de la función pueden
a menudo ser beneficiosos al reducir la disfunción cognitiva inducida por la enfermedad. Otra aplicación
importante es la identificación de los beneficios de compuestos diseñados para reforzar la función cogniti-
va. Tales efectos pueden ser explorados en los típicos ensayos de fase I; también el modelo de la scopolami-
na de los principales déficits de la enfermedad de Alzheimer  puede ser utilizado para identificar potencia-
les fármacos antidemencia. A fin de cuentas, dichos efectos pueden ser demostrados empleando
procedimientos automatizados correctamente validados y altamente sensibles en poblaciones blanco. Los
datos presentados demuestran que el concepto de la evaluación independiente de una variedad de funcio-
nes cognitivas es crucial para ayudar a diferenciar fármacos, tipos de demencia y distintas enfermedades.
Dicha información permite un análisis exclusivo acerca de la forma cómo las alteraciones de varias funcio-
nes cognitivas se manifestarán en las conductas de la vida diaria. Esto revela una limitación importante de
las escalas que entregan sólo un puntaje, puesto que esta información reducida no permite más que una
interpretación cuantitativa y el concepto de “mayor o menor” función cognitiva es manifiestamente ina-
propiado para algo tan complejo y diverso como la integración entre el funcionamiento cognitivo y la con-
ducta humana. Finalmente se describen las futuras generaciones de pruebas cognitivas. La evaluación por
vía telefónica se ha introducido recientemente y tendrá efectos significativos en la logística de la realización
de pruebas cognitivas en grandes poblaciones de pacientes de ensayos clínicos. La evaluación por vía de inter-
net no está lejos de utilizarse dado el alto número de hogares que se están conectando a la red en Europa
y Norteamérica. No hay razones fundadas para no querer incluir las pruebas de función cognitiva en el desa-
rrollo de protocolos de cualquier nuevo medicamento. 
of Dementia: A Manual for Memory Disorders Teams. Oxford, UK: Oxford
University Press; 1999:124-136.
12. Wesnes KA, Mount RH, Stephenson N, Lockton JA, Rolan P. A compar-
ison of computerized and non-computerized cognitive assessments. J
Psychopharmacol. 1996;10(suppl):A29.
13. Wesnes KA, O’Neill ST. Benzodiazepines affect simple not choice reac-
tion time in a choice reaction time task. J Psychopharmacol.
1996;10(suppl):A52.
14. Wesnes KA, Simpson P, White L, Pinker S. The Cognitive Drug Research
computerized assessment systems for elderly, AAMI and demented
patients. J Psychopharmacol. 1992;6:108.
15. Wesnes KA, Simpson PM, Christmas L. The assessment of human infor-
mation processing abilities in psychopharmacology. In: Hindmarch I,
Stonier PD, eds. Human Psychopharmacology: Measures and Methods. Vol 1.
Chichester, UK: Wiley; 1987:79-92.
16. Jones S, Jensen NO, Oliver S, Wesnes KA. Cognitive effects of single
doses of ME3127, a novel anxiolytic in volunteers. J Psychopharmacol.
1999;13(suppl A):A27.
17. McEwen J, Wesnes KA, Rapeport WG, Williams S. The cognitive effects
of single and multiple doses of UK 76,654, a selective M3 muscarinic
antagonist in healthy volunteers. Eur J Clin Invest. 1995;25(suppl 2):A64.
18. Russell-Duff K, Jensen NO, Mooney P, Wesnes KA. Cognitive effects of
NS2389, a serotonin reuptake inhibitor, in healthy volunteers. J
Psychopharmacol. 1999;13(suppl A):A27.
19. Pincock C, Jensen NO, Oliver S, Wesnes KA, Jones S. Cognitive effects
of multiple doses of ME3127, a novel anxiolytic, in volunteers. J
Psychopharmacol. 1999;13(suppl A):A27.
20. Holland RL, Wesnes KA, Dietrich B. Single-dose human pharmacology
of umespirone. Eur J Clin Pharmacol. 1994;46:461-468.
21. Wilcox C, Wesnes KA, Heiser J, Simpson P, Katz B, Happy J. A double-
blind, eight-way crossover comparison of abecarnil, lorazepam and place-
bo alone and after a single dose of alcohol, on psychometric performance
in healthy volunteers. Psychopharmacol Bull. 1996;32:536.
22. Wesnes KA, de Koning P, Dietrich B. A comparison of the cognitive
effects of DU29894, sulpiride, haloperidol and a selective 5HT1A agonist in
normal volunteers. Eur J Clin Invest. 1995;25(suppl 2):A64.
C l i n i c a l  r e s e a r c h
198
Valeur de l’évaluation de la fonction cognitive dans le développement d’une molécule
Quelles sont la valeur et l’utilité de la mesure de la fonction cognitive dans le développement des
nouvelles molécules ? Telle est la question traitée dans cet article en référence au système automa-
tisé le plus largement utilisé en recherche clinique. Le système d’évaluation informatisé de “ Cogni-
tive Drug Research “ sur les études en cours a fait la preuve de la qualité et de la nature des infor-
mations obtenues en phase I à III, même au cours de la première étude dans laquelle un nouveau
composé est administré à l’homme. De tels essais permettent d’une part de s’assurer de l’innocuité
des nouvelles molécules sur la fonction cognitive surtout en ce qui concerne les molécules concur-
rentielles, d’autre part de veiller à l’absence d’interactions indésirables médicamenteuses ou avec l’al-
cool ou de les situer dans leur contexte. Chez beaucoup de patients, l’altération de la fonction cogni-
tive résulte d’un processus pathologique dont les symptômes peuvent être traités par de nouveaux
produits sans effets délétères supplémentaires et dont le bénéfice se révèlera au fur et à mesure de
l’amélioration de la fonction cognitive. Certaines molécules permettent aussi d’améliorer la fonction
cognitive de base et cette amélioration peut être mesurée. De tels effets peuvent être recherchés en
phase 1 des essais cliniques ou bien en utilisant un modèle des principaux déficits cognitifs de la mala-
die d’Alzheimer induits par la scopolamine dans la recherche des molécules antidémentielles. Tout
compte fait, seules des procédures très sensibles et fiables sur des populations cibles permettront leur
mise en évidence. Les données présentées démontrent que le concept d’évaluation des fonctions
cognitives de façon indépendante est primordial pour permettre de différencier les thérapeutiques,
les types de démence et les différentes maladies. Une telle information offre une perception unique
de la façon dont les altérations de la fonction cognitive se manifestent au quotidien. Les échelles à
score unique qui n’autorisent qu’une interprétation quantitative montrent ici leurs limites et le
concept de fonction “ plus ou moins cognitive “ se révèle inapproprié pour une notion aussi com-
plexe et variée que l’interaction entre fonction cognitive et comportement humain. En dernier lieu,
les nouvelles générations de tests cognitifs sont décrites. Les méthodes de test par téléphone sont
récentes et vont bouleverser la logistique des tests cognitifs sur les études à grand effectif. Dans un
avenir proche, les tests se feront par Internet, proportionnellement au nombre de foyers connectés
en Europe et en Amérique du Nord. Il n’existe pas de raisons valables de vouloir exclure les tests des
fonctions cognitives du développement de la médecine du futur.
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